A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.
Quick Facts
What This Study Found
RTP004 enhances presynaptic binding and reduces post-injection diffusion of botulinum toxin.
Key Numbers
How They Did This
The study discusses the formulation characteristics and pharmacological properties of RTP004 in relation to botulinum toxin.
Why This Research Matters
This research represents a breakthrough in drug delivery systems, potentially improving the efficacy of botulinum toxin treatments. The approval of RTP004-containing products could lead to better therapeutic outcomes in clinical settings.
What This Study Doesn't Tell Us
The study primarily focuses on the formulation and does not provide extensive clinical trial data on efficacy and safety.
Trust & Context
- Original Title:
- A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.
- Published In:
- Expert opinion on drug delivery, 20(9), 1157-1166 (2023)
- Database ID:
- RPEP-06846
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06846APA
Dowdy, Steven F; Gallagher, Conor J; Vitarella, Domenico; Brown, Jessica. (2023). A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.. Expert opinion on drug delivery, 20(9), 1157-1166. https://doi.org/10.1080/17425247.2023.2251399
MLA
Dowdy, Steven F, et al. "A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.." Expert opinion on drug delivery, 2023. https://doi.org/10.1080/17425247.2023.2251399
RethinkPeptides
RethinkPeptides Research Database. "A technology evaluation of the atypical use of a CPP-contain..." RPEP-06846. Retrieved from https://rethinkpeptides.com/research/dowdy-2023-a-technology-evaluation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.